Precipio to Report $15.2M for FY-2023 (unaudited) Revenues, an increase of 60% YoYGlobeNewsWire • 02/13/24
Precipio and Cardinal Health Sign Distribution Agreement for its HemeScreen® Portfolio of Molecular assays for CancerGlobeNewsWire • 02/06/24
Precipio's Q4-2023 Cash Burn From Operations (unaudited) drops below $100K for the full quarterGlobeNewsWire • 01/23/24
Precipio's Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023GlobeNewsWire • 10/03/23
Precipio's Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of PlanGlobeNewsWire • 09/13/23
Precipio's Operational Efficiency Measures Continue To Reduce Cash Burn And Move The Company Towards BreakevenGlobeNewsWire • 08/03/23
Precipio Unaudited Q2-2023 Revenues Show combined increase of 25% over Q1-2023GlobeNewsWire • 08/01/23
Precipio's Omnia™ Methodology Enables Diagnosis of MDS With Peripheral Blood Instead of Bone Marrow BiopsyGlobeNewsWire • 06/14/23
Precipio Enters into Collaboration with Prestigious New York-based Institution to Develop Revolutionary Brain Tumor Panel using HemeScreen® TechnologyGlobeNewsWire • 06/13/23
Precipio, Inc. Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private PlacementGlobeNewsWire • 06/08/23
Projected cash burn reduced by $1.5 million annually from Three Operational Efficiency ProjectsGlobeNewsWire • 06/07/23
Precipio's Lab Detects BCR-ABL1 Oncogene Co-Expression of p190 & p210 Isoforms in a CML Patient By Using HemeScreen® TechnologyGlobeNewsWire • 05/22/23